MMP-2 Inhibitor I (Synonyms: Matrix Metalloproteinase-2 Inhibitor I,cis-9-Octadecenoyl-N-hydroxylamide,Oleylhydroxamate) |
Catalog No.GC17738 |
reversible inhibitor of matrix metalloproteinase (MMP)-2
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 10335-69-0
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
MMP-2 Inhibitor I, a hydroxamate-based, long-chain fatty acid, is a reversible inhibitor of matrix metalloproteinase (MMP)-2.
Matrix metalloproteinases (MMPs) have been involved in the degradation of extracellular matrix. MMPs contribute to long-term remodeling processes such as embryogenesis, tumor invasion, inflammation, angiogenesis, and wound healing. MMP-2, also known as gelatinase A or type IV collagenase, has been involved in regulating diverse cellular functions independent of its action on the extracellular matrix, including vascular tone, platelet aggregation, and mediation of the acute mechanical dysfunction of the heart immediately after ischemia and reperfusion [2]. Up-regulation of MMP-2 has been associated with tumor invasion and metastasis [3].
MMP-2 Inhibitor I inhibited the activity of matrix metalloproteinase (MMP)-2 with the Ki value of 1.6 μM [1]. MMP-2 Inhibitor I attenuated cancer cell migration [3]. MMP-2 Inhibitor I had also been used to preserve blood-brain barrier function in a Wistar rat model of pneumococcal meningitis [4].
References:
[1] Berton A, Rigot V, Huet E, et al. Involvement of fibronectin type II repeats in the efficient inhibition of gelatinases A and B by long-chain unsaturated fatty acids[J]. Journal of Biological Chemistry, 2001, 276(23): 20458-20465.
[2] Wang W, Schulze C J, Suarez-Pinzon W L, et al. Intracellular action of matrix metalloproteinase-2 accounts for acute myocardial ischemia and reperfusion injury[J]. Circulation, 2002, 106(12): 1543-1549.
[3] Emmert-Buck M R, Roth M J, Zhuang Z, et al. Increased gelatinase A (MMP-2) and cathepsin B activity in invasive tumor regions of human colon cancer samples[J]. The American journal of pathology, 1994, 145(6): 1285.
[4] Barichello T, Generoso J S, Michelon C M, et al. Inhibition of matrix metalloproteinases-2 and-9 prevents cognitive impairment induced by pneumococcal meningitis in Wistar rats[J]. Experimental Biology and Medicine, 2014, 239(2): 225-231.
Cas No. | 10335-69-0 | SDF | |
Synonyms | Matrix Metalloproteinase-2 Inhibitor I,cis-9-Octadecenoyl-N-hydroxylamide,Oleylhydroxamate | ||
Chemical Name | N-hydroxy-9Z-octadecenamide | ||
Canonical SMILES | ONC(CCCCCCC/C=C\CCCCCCCC)=O | ||
Formula | C18H35NO2 | M.Wt | 297.5 |
Solubility | ≤50mg/ml in ethanol;50mg/ml in DMSO;50mg/ml in dimethyl formamide | Storage | Store at -20°C; protect from light |
General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. |
Prepare stock solution | |||
1 mg | 5 mg | 10 mg | |
1 mM | 3.3613 mL | 16.8067 mL | 33.6134 mL |
5 mM | 0.6723 mL | 3.3613 mL | 6.7227 mL |
10 mM | 0.3361 mL | 1.6807 mL | 3.3613 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Average Rating: 5
(Based on Reviews and 8 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *